Douglas Short, MD
Internal Medicine · Raleigh, NCNPI 1922148923
Payments from drug & device makers
Across 117 payments — averaging $106.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- AbbVie$277
- Novo Nordisk$260
- Amgen$243
- Merck$116
- AstraZeneca$83
- plus $897 from 27 others
What the payments were for
- Food & beverage$1,973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $10,616 |
| AbbVie | 18 | $277 |
| Novo Nordisk | 14 | $260 |
| Amgen | 16 | $243 |
| Merck | 7 | $116 |
| AstraZeneca | 5 | $83 |
| Lilly USA, LLC | 4 | $68 |
| Exact Sciences | 4 | $66 |
| GSK | 5 | $63 |
| Novartis | 4 | $62 |
| Astellas Pharma US Inc | 3 | $59 |
| Abbott | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Abiomed | 1 | $39 |
| Medtronic | 2 | $39 |
| Pfizer | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Gilead | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $24 |
| Halozyme Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Biogen | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
How this compares
$12,492 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $137,677 |
| MounjaroTirzepatide | 94 | $98,773 |
| OzempicSemaglutide | 76 | $78,410 |
| XareltoRivaroxaban | 30 | $35,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $30,172 |
| JardianceEmpagliflozin | 19 | $22,751 |
| Repatha SureclickEvolocumab | 13 | $11,680 |
| MyrbetriqMirabegron | 12 | $11,422 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $11,222 |
| SynthroidLevothyroxine Sodium | 69 | $7,543 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,821 |
| Testosterone | 29 | $5,554 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,838 |
| Levothyroxine Sodium | 180 | $3,789 |
| Atorvastatin Calcium | 323 | $3,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $137,677108 claims |
| Lilly USA, LLCMounjaro | $68 | $98,77394 claims |
| Novo NordiskOzempic | $260 | $78,41076 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $63 | $47,21577 claims |
| Boehringer IngelheimJardiance | $10,616 | $22,75119 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $11,42212 claims |
| AbbVieSynthroid | $277 | $7,54369 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $3,789180 claims |
| Sanofi-aventis U.S. LLCLantus | $17 | $1,41814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.